Lipella pharmaceuticals completes enrollment in phase 2a trial of lp-310 for oral lichen planus

Pittsburgh, april 08, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its phase 2a multicenter, dose-ranging trial evaluating lp-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (olp). the phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven u.s. study sites.
LIPO Ratings Summary
LIPO Quant Ranking